CAS Investment Partners, LLC: CARDLYTICS INC (CDLX): Quarterly 13F Position History
As of Q1 2026, CAS Investment Partners, LLC reported 5,198,067 shares of CARDLYTICS INC (CDLX), worth $5.5M and representing 0.3% of its 13F equity book. The position first appeared in Q2 2019 and has been disclosed across 28 13F-HR filings in Pactolio's tracked window.
- 5,198,067Shares Held (Latest Filing)
- $5.5MReported Market Value (Latest Filing)
- 0.3%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$519.8KQuarter-over-Quarter Value Change
- 6,464,859Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 28 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 5,198,067 | 0 | — | $5.5M | 0.3% | $1.1 |
| Q4 2025 | 5,198,067 | 0 | — | $6.0M | 0.3% | $1.1 |
| Q3 2025 | 5,198,067 | 415,855 | -7.4% | $12.6M | 0.6% | $2.4 |
| Q2 2025 | 5,613,922 | 0 | — | $9.2M | 0.5% | $1.6 |
| Q1 2025 | 5,613,922 | 754,988 | -11.9% | $10.2M | 0.7% | $1.8 |
| Q4 2024 | 6,368,910 | 50,823 | -0.8% | $23.6M | 1.4% | $3.7 |
| Q3 2024 | 6,419,733 | 45,126 | -0.7% | $20.5M | 1.4% | $3.2 |
| Q2 2024 | 6,464,859 | +91,183 | +1.4% | $53.1M | 4.1% | $8.2 |
| Q1 2024 | 6,373,676 | +957,560 | +17.7% | $92.4M | 8.3% | $14.5 |
| Q4 2023 | 5,416,116 | 0 | — | $49.9M | 6.0% | $9.2 |
| Q3 2023 | 5,416,116 | 0 | — | $89.4M | 11.5% | $16.5 |
| Q2 2023 | 5,416,116 | 0 | — | $34.2M | 5.2% | $6.3 |
| Q1 2023 | 5,416,116 | 0 | — | $18.4M | 3.8% | $3.4 |
| Q4 2022 | 5,416,116 | 0 | — | $31.3M | 7.5% | $5.8 |
| Q3 2022 | 5,416,116 | 0 | — | $50.9M | 9.3% | $9.4 |
| Q2 2022 | 5,416,116 | 0 | — | $120.8M | 18.3% | $22.3 |
| Q1 2022 | 5,416,116 | +229,650 | +4.4% | $297.8M | 19.9% | $55.0 |
| Q4 2021 | 5,186,466 | +36,875 | +0.7% | $342.8M | 17.9% | $66.1 |
| Q3 2021 | 5,149,591 | +660,619 | +14.7% | $432.3M | 20.6% | $83.9 |
| Q2 2021 | 4,488,972 | 0 | — | $569.8M | 24.2% | $126.9 |
| Q1 2021 | 4,488,972 | 0 | — | $492.4M | 25.2% | $109.7 |
| Q4 2020 | 4,488,972 | +97,386 | +2.2% | $640.9M | 35.5% | $142.8 |
| Q3 2020 | 4,391,586 | +377,337 | +9.4% | $309.9M | 21.5% | $70.6 |
| Q2 2020 | 4,014,249 | +62,734 | +1.6% | $280.9M | 30.2% | $70.0 |
| Q1 2020 | 3,951,515 | +1,129,805 | +40.0% | $138.1M | 30.4% | $35.0 |
| Q4 2019 | 2,821,710 | +502,299 | +21.7% | $177.4M | 29.2% | $62.9 |
| Q3 2019 | 2,319,411 | +157,391 | +7.3% | $77.7M | 17.2% | $33.5 |
| Q2 2019 | 2,162,020 | — | — | $56.2M | 14.4% | $26.0 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did CAS Investment Partners, LLC first disclose a CDLX position in 13F-HR filings?
CAS Investment Partners, LLC first reported CARDLYTICS INC (CDLX) on its 13F-HR filing for the period ending 2019-06-30 (Q2 2019). The position has appeared on 28 reported quarters within Pactolio's tracked window.
What was CAS Investment Partners, LLC's most recent quarter-over-quarter share-count change in CDLX?
CAS Investment Partners, LLC held the same 5,198,067 shares of CDLX between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent CAS Investment Partners, LLC's cost basis in CDLX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.